NVSNovartis PharmaceuticalsRunning, no new patients
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
Relapsing Multiple Sclerosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,000 (final count)
- Started
- Dec 16, 2021
- Main results expected
- Jul 21, 2026
- Fully finished
- Oct 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Measured over: From Baseline, up to 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05147220 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC